Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Northwestern University

Extramedullary disease such as CNS involvement is quite uncommon at diagnosis in acute promyelocytic leukemia (APL). However, it can be seen in patients with relapsed disease. Both isolated CNS relapse and CNS relapse associated with morphologic or molecular relapse can occur. Yet one has the impres...

What are common indications for ordering NGS of peripheral blood?

2
1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

I am delighted that someone posed this question because, in my experience as a consultant hematologist, it appears that advances in DNA sequencing technology have outstripped the knowledge base of many practitioners. This is not due to lack of interest or due diligence on their part, but rather beca...

What are common indications for ordering NGS of peripheral blood?

2
1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

I am delighted that someone posed this question because, in my experience as a consultant hematologist, it appears that advances in DNA sequencing technology have outstripped the knowledge base of many practitioners. This is not due to lack of interest or due diligence on their part, but rather beca...

What, if any, resources exist with recommendations regarding the timing and toxicity of radiation in patients who have received or are currently on immunotherapy?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

Concurrent immunotherapy (PD1/PDL1) with chemoradiation is now not advised, given the two negative lung cancer trials (PACIFIC 2, CheckMate 73L). Concurrent immunotherapy with radiation alone is still an interesting area to explore, as the two published studies (SPRINT, Ohri et al., PMID 37988638, a...

What would you use for cytoreduction in a pregnant patient with high risk ET and APLS?

1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

My first instinct in replying to this question is to understand the basis for the diagnosis of “high-risk ET”. Since the patient is pregnant, the basis for the designation “high-risk” must be a history of a prior thrombotic event, either arterial or venous. However, the purveyors of the various MPN ...

What would you use for cytoreduction in a pregnant patient with high risk ET and APLS?

1 Answers

Mednet Member
Mednet Member
Hematology · Johns Hopkins University

My first instinct in replying to this question is to understand the basis for the diagnosis of “high-risk ET”. Since the patient is pregnant, the basis for the designation “high-risk” must be a history of a prior thrombotic event, either arterial or venous. However, the purveyors of the various MPN ...

Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

It would depend on how long the patient has been on imatinib and the sensitivity of PCR testing. Being able to monitor the p230 transcript at the level of 0.1% or even deeper would be helpful to characterize if the patient has achieved a major molecular response or not. This publication outlines the...

What is your approach for bulky stage I primary mediastinal B-cell lymphoma in a patient with a positive post-chemotherapy PET-CT (residual mass and Deauville 5)?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

Interpreting end-of-treatment PET in PMBL can be tricky. False positives here are very common! Fake-outs include thymic rebound masquerading as refractory disease; avidity at rim (which is almost always biopsy-neg); or residual avidity throughout residual mass which again can be biopsy negative. I w...

What is your approach for bulky stage I primary mediastinal B-cell lymphoma in a patient with a positive post-chemotherapy PET-CT (residual mass and Deauville 5)?

2
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

Interpreting end-of-treatment PET in PMBL can be tricky. False positives here are very common! Fake-outs include thymic rebound masquerading as refractory disease; avidity at rim (which is almost always biopsy-neg); or residual avidity throughout residual mass which again can be biopsy negative. I w...

How would you approach therapy for a nasal high grade neuroendocrine tumor with ipsilateral local cervical adenopathy?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

A couple of additional thoughts on work-up: Is the pathologist calling this small cell histology (as opposed to SNUC, esthesioneuroblastoma, etc) or a low grade NEC? I would also request tumor NGS and PD-L1. MRI brain to r/o mets if not done already should be considered. If it is high grade, I wou...